Irbesartan/Hydrochlorothiazid Heumann

Irbesartan, the active ingredient in Irbesartan/Hydrochlorothiazid Heumann, is an Angiotensin II receptor blocker presented as an oral tablet for oral use. It helps lower blood pressure in adults with hypertension.

GNH USA supplies Irbesartan/Hydrochlorothiazid Heumann as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Irbesartan/Hydrochlorothiazide is used to treat conditions within the hypertension disease family.

Hypertension: reduces systolic and diastolic blood pressure in patients with elevated readings. Left ventricular hypertrophy: helps prevent progression of pressure‑induced cardiac remodeling. Proteinuria associated with hypertension: decreases urinary protein excretion and protects renal function.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue or weakness - Increased urination - Electrolyte disturbances (e.g., low potassium) - Mild gastrointestinal upset

Serious or Rare Side Effects: - Severe dehydration or electrolyte imbalance - Acute kidney injury or worsening renal function - Hyperkalemia or severe hypokalemia - Allergic reactions such as rash, angioedema, or anaphylaxis - Blood dyscrasias (e.g., agranulocytosis, thrombocytopenia) - Hepatic dysfunction or jaundice

Before initiating therapy, consider the following precautions.

Monitor blood pressure regularly: ensure therapeutic response and avoid hypotension. Assess renal function: check serum creatinine and eGFR at baseline and periodically. Check electrolytes: especially potassium and sodium levels. Avoid use in severe hepatic impairment: dose adjustments may be required. Use caution in elderly patients: increased sensitivity to blood pressure changes. Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Irbesartan/Hydrochlorothiazide may interact with several medicines.

Major Interactions (Avoid): - Aliskiren: combined use can increase risk of renal impairment. - Potassium‑sparing diuretics or supplements: may cause dangerous hyperkalemia. - Lithium: can raise lithium levels, leading to toxicity. - ACE inhibitors or other ARBs: additive effects on potassium and renal function. - NSAIDs: may reduce antihypertensive efficacy and impair renal function.

Moderate Interactions (Monitor Closely): - Other thiazide or loop diuretics: monitor electrolytes and volume status. - Antihypertensive agents (beta‑blockers, calcium channel blockers): may enhance blood pressure lowering. - CYP2C9 inhibitors (e.g., fluconazole): can increase irbesartan plasma concentrations. - Antidiabetic drugs: diuretic‑induced changes in glucose control may require dose adjustment. - Anticoagulants: diuretic‑induced dehydration may affect INR stability.